Infinity Pharmaceuticals (NASDAQ: INFI) novel approach is based on Targeting Immune Suppressive Macrophages by selectively inhibiting PI3K-Gamma. The Company’s lead candidate eganelisib, is a first-in-class, oral, once-daily selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma), that has the potential to transform the immuno-oncology space. IPI-549 has demonstrated...
Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) was one of our stock picks this week based on its promising pipeline and an impending FDA approval for FOTIVDA® (tivozanib). The Company has scored a big win with its approval, which not only validates its unique approach but also...
Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...
Sesen Bio, Inc. (NASDAQ: SESN) is focused on creating targeted fusion protein therapeutics (TFPTs) for treatment of cancers. The Company is looking at a major catalyst in 2021, the approval of Vicineum, a potential best-in-class therapeutic for the treatment of non-muscle invasive bladder cancer (NMIBC)...
Magenta Therapeutics Inc (NASDAQ: MGTA), a Company pioneering research in stem cell transplant to reset the immune system in order to combat autoimmune, blood cancers and genetic diseases, provided a development update for MGTA-145, a CXCR2 agonist that is intended as a first-line therapy for...
Fennec Pharmaceuticals (NASDAQ: FENC), a small–stage biotechnology Company, announced the grant of a patent 10,596,190 entitled “Method for Reducing Ototoxicity in Pediatric Patients Receiving Platinum-Based Chemotherapy.” by the U.S. Patent and Trademark Office. The Company’s PEDMARK, which uses the patented technology, is a novel formulation...
Kannalife Inc (OTCQB: KLFE), a biopharmaceutical Company developing CBD-based therapeutics for the treatment of neurodegenerative and neuropathic pain disorders, announced the grant of a patent Chinese Patent CN106456573B specific to "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy",...
Inhibitor Therapeutics (OTCQB: INTI), a Biopharmaceutical Company focussed on addressing the unmet medical needs in the field of cancerous and non-cancerous proliferation disorders, announced the receipt of an Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for traconazole, intended for...
Accuray Inc (NASDAQ: ARAY), a Company developing robotic stereotactic radiosurgery and stereotactic body radiation therapy system, specifically the CyberKnife System, announced the data from a prospective study which demonstrates the efficacy and safety of its stereotactic body radiation therapy (SBRT), administered using the CyberKnife system....
Profound Medical Corp (NASDAQ: PROF), a medical technology Company that offers magnetic resonance guided ablation procedures, announced the approval of its TULSA-PRO® system for the ablation of low to intermediate risk organ-confined prostate cancer by Heath Canada. The Company develops innovative, customizable, incision-free and radiation free...
